Ma Ai Thanda Han

Assistant Professor/Transplant Hepatologist; Fellow@MayoClinic, Rochester @MayoClinicGIHep, @CedarsSinai,@NIH/NIDDK.Tweets are mine, not medical advice

[Ma Ai Thanda Han @thandahan]

@Oby_Ez Thanks

[Ma Ai Thanda Han @thandahan]

Pleased to share my promotion to Associate Clinical Professor of Medicine at the University of Arizona – Phoenix. Grateful to my mentors, colleagues, trainees, patients, and family for their support. Looking forward to advancing patient care, education, mentorship, and research.

[Ma Ai Thanda Han @thandahan]

@Will_Sanchez_MD Thank you. I truly appreciate your support and mentorship over the years.

[Ma Ai Thanda Han @thandahan]

Truly honored and humbled to receive the Faculty Mentor of the Year Award (2026) from University of Arizona College of Medicine/ Banner University Medical Center Phoenix. Teaching and mentorship have always been among the most rewarding parts of academic medicine.

[Ma Ai Thanda Han @thandahan]

Honored to present our poster at EASL Congress 2026 today. Looking forward to sharing our research, learning from colleagues worldwide, and participating in this year’s EASL scientific sessions
#EASL2026 #MASLD #FattyLiver @UATransplantHep @UAzMedPhxChair @diwanshusoni24

[Ma Ai Thanda Han @thandahan]

Excited to present our poster at EASL Congress 2026 this Saturday! Barcelona, Spain
📍 SAT-220 | Hall 7
🕣 May 30, 08:30 CEST
Please stop by if you are attending EASL 😊
#EASL2026 #MASLD #FattyLiver @UATransplantHep @UAzMedPhxChair

[Ma Ai Thanda Han @thandahan]

Excited to share our recent publication in Transplant Direct highlights the impact of GLP-1 receptor agonists and SGLT2 inhibitors on post-liver transplant outcomes, including MACE, graft failure, renal outcomes &mortality
https://t.co/oQYMfw9iQ6
@UATransplantHep @UAzMedPhxChair

[AASLD @AASLDtweets]

🔥 HOT TOPIC

📗 @HEP_Journal #HEPATOLOGY

Selected for its clinical impact, this meta-analysis delivers critical insights into which anti-diabetic therapies may also reduce liver-related events in patients with #MASLD.

For clinicians managing the complex overlap of #diabetes and liver disease, these findings could directly inform treatment decisions and improve patient outcomes.

Read the full study here: https://t.co/VXgqkJAhFQ

[Ma Ai Thanda Han @thandahan]

Real-world data in clinical practice
identify CSPH with VTCE & Plt
VTCE15-20+plt <110
VTCE 20-25+ plt < 150
VTCE >25 + any plt
NSBB for cACLD with CSPH
Telepression+Albumin - 1st line for HRS-AKI
Resp Failure Risks- ACLF3 & Hypoxia
#TLM25 @AASLDtweets

[Ma Ai Thanda Han @thandahan]

Hearty congratulations to my accomplished residents and student for earning a poster of distinction presentation at AASLD in Washington, DC. #TLM25 @AASLDtweets @UATransplantHep @UAzMedPhxChair @uazmedphx @UAPhxIM

[UACOM-P Transplant Hepatology Fellowship @UATransplantHep]

So proud of our residents, fellows and faculty for their work being showcased at #TLM25! 🎓📑👏🏾
@AASLDtweets @UAPhxIM @UAzMedPhxChair

[Ma Ai Thanda Han @thandahan]

Kudos to the team. @diwanshusoni24 for a great presentation and discussion at AASLD #TLM25 @AASLDtweets @UATransplantHep @UAzMedPhxChair @uazmedphx
@diwanshusoni24 @LeithGhani @Chi_hua_Chung

[Ma Ai Thanda Han @thandahan]

Funtime- University of Arizona Liver Family's Dinner at AASLD 2025, Washington DC #TLM25 @AASLDtweets @UATransplantHep @UAzMedPhxChair

[Ma Ai Thanda Han @thandahan]

Takeaway-Obesity Medicine Course -2 re: MALSD & MET-ALD
-importance to recognize effect of alcohol on post bariatric Sx- emerging MET-ALD
- Drinking & Obesity in development of ALD
- High Protein diet is important to prevent obesity sarcopenia
@AASLDtweets #TLM25

[Ma Ai Thanda Han @thandahan]

Takeaway - Obesity Medicine Course 1 re: MASLD/ METALD
- address -addiction behavior to food cravings/Binge eating Do and alcohol
- Obesity - not just BMI, clinical manifestation is important in Mx #TLM25 @AASLDtweets

[Ma Ai Thanda Han @thandahan]

Highlight- Expert Perspective on Dx and Mx of MASH #TLM25 @AASLDtweets

[Ma Ai Thanda Han @thandahan]

Come check out our research poster of distinction on Monday Nov 10, 2025 at Hall DE #TLM25 @AASLDtweets @AASLDPresident @UATransplantHep @UAzMedPhxChair

[Dr. AK 🇮🇳 @docakx]

The 2025 AASLD/IDSA Practice Guideline on the treatment of chronic hepatitis B was released on their website on November 4, 2025.

Here’s what has changed compared to the previous 2018 guidelines, according to ChatGPT.

🔴Pregnancy — antiviral prophylaxis to prevent mother-to-child transmission (MTCT)

• 2018: Suggest antiviral therapy in the third trimester for women with HBV DNA >200,000 IU/mL; TDF preferred in pregnancy; antiviral prophylaxis could be stopped at delivery or up to 4 weeks postpartum.

• 2025: Strong recommendation to start TDF (preferred) or TAF for persons with HBV DNA >200,000 IU/mL, optimally at gestational week 28 (third trimester). Adds that TAF has accumulating safety data and that earlier start (week 16) may be considered when infant HBIG is not available; recommends that prophylaxis can be stopped at delivery if there is no ongoing maternal indication, and gives detailed monitoring after discontinuation.

🔴Drugs preferred in pregnancy
• 2018: TDF preferred (TAF was newly approved but data limited for pregnancy); lamivudine/telbivudine shown to reduce MTCT historically but TDF preferred.

• 2025: TDF (preferred) or TAF (safety data reviewed) — TAF specifically acknowledged as an option with data cited. Notes insufficient safety data to recommend entecavir in pregnancy.

🔴Timing of prophylaxis (earlier initiation / special circumstances)
• 2018: Recommended third-trimester (generally) for high viral load; postpartum monitoring advised.

• 2025: Keeps week-28 initiation as optimal but adds: consider starting at week 16 to control viremia when infant HBIG isn’t available (new RCT evidence cited); also suggests earlier initiation if invasive procedures (e.g., amniocentesis) are anticipated.

🔴High-risk transmission (HBsAg+ persons in settings with risk of infecting others)
• 2018: Emphasized counseling, vaccination of contacts, and reducing exposure; antiviral therapy for prevention considered in pregnancy/high-risk situations.

• 2025: For viremic persons not meeting disease-specific treatment criteria but in high-risk transmission scenarios, the guideline suggests shared decision-making about antiviral therapy (conditional, very low certainty). Implementation considerations expanded (vaccination status of contacts, immunocompromised contacts, etc.).

🔴Immune-tolerant phase (HBeAg+, very high HBV DNA, normal ALT)
• 2018: Generally did not recommend treatment for true immune-tolerant adults; treatment was recommended for immune-active disease; caution about treating children/adolescents — monitor for transition. (Third-trimester pregnancy guidance separate.)

• 2025: Refines the approach: suggests antiviral therapy for immune-tolerant persons >40 years or those with significant inflammation (≥G2) or fibrosis (≥F2); for persons <40 years without fibrosis/inflammation the guideline recommends shared decision-making and periodic monitoring. (So the 2025 guidance provides clearer age/fibrosis/inflammation thresholds.)

🔴Indeterminate phase (HBeAg-negative, non-cirrhotic with intermediate labs)
• 2018: Recommended individualized decisions; monitor and treat when meeting immune-active criteria.

• 2025: Explicitly recommends shared decision-making for these HBeAg-negative, indeterminate patients and emphasizes reassessment at each visit if treatment is deferred (conditional recommendation, very low certainty).

[Ma Ai Thanda Han @thandahan]

Please join us for our research oral presentation in Ballroom A, level 3 on Sunday, Nov 9, 2025, at 5 pm #TLM25 @AASLDtweets @AASLDFoundation @UATransplantHep @UAzMedPhxChair

[Ma Ai Thanda Han @thandahan]

Excited to be attending #TLM25 this year! It’s where hepatology professionals from around the world come together to share discoveries and impact the future of liver health. Register on-site (until Nov. 10th) or here 👉
https://t.co/h4WMoAG1ut @AASLDtweets @AASLDFoundation